BRAIN Biotech Future Growth
Future criteria checks 4/6
BRAIN Biotech is forecast to grow earnings and revenue by 69.6% and 8.9% per annum respectively while EPS is expected to grow by 69.6% per annum.
Key information
69.6%
Earnings growth rate
69.62%
EPS growth rate
| Chemicals earnings growth | 37.6% |
| Revenue growth rate | 8.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 16 Jan 2026 |
Recent future growth updates
Recent updates
Market Cool On BRAIN Biotech AG's (ETR:BNN) Revenues Pushing Shares 28% Lower
Dec 22
It's A Story Of Risk Vs Reward With BRAIN Biotech AG (ETR:BNN)
Nov 07Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Aug 26A Piece Of The Puzzle Missing From BRAIN Biotech AG's (ETR:BNN) 38% Share Price Climb
Jul 23Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce
Nov 12Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce
Sep 24BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch
Aug 06Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Jun 29BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate
Apr 19BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable
Mar 28Is BRAIN Biotech (ETR:BNN) A Risky Investment?
Feb 16Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt
Sep 13Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like
Mar 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2028 | 64 | -5 | N/A | N/A | 2 |
| 9/30/2027 | 67 | 0 | -7 | -4 | 5 |
| 9/30/2026 | 57 | -4 | -8 | -5 | 5 |
| 9/30/2025 | 51 | -12 | -11 | -9 | N/A |
| 6/30/2025 | 54 | -12 | -9 | -8 | N/A |
| 3/31/2025 | 54 | -14 | -7 | -5 | N/A |
| 12/31/2024 | 56 | -13 | -6 | -4 | N/A |
| 9/30/2024 | 55 | -11 | -5 | -4 | N/A |
| 6/30/2024 | 56 | -9 | -5 | -2 | N/A |
| 3/31/2024 | 56 | -8 | -4 | -2 | N/A |
| 12/31/2023 | 55 | -8 | -7 | -5 | N/A |
| 9/30/2023 | 56 | -8 | -7 | -4 | N/A |
| 6/30/2023 | 55 | -7 | -11 | -5 | N/A |
| 3/31/2023 | 54 | -7 | -11 | -6 | N/A |
| 12/31/2022 | 54 | -7 | -9 | -3 | N/A |
| 9/30/2022 | 50 | -7 | -8 | -1 | N/A |
| 6/30/2022 | 48 | -8 | -3 | -2 | N/A |
| 3/31/2022 | 44 | -8 | -4 | -1 | N/A |
| 12/31/2021 | 41 | -4 | -3 | -2 | N/A |
| 9/30/2021 | 39 | -5 | -5 | -4 | N/A |
| 6/30/2021 | 37 | -6 | -5 | -2 | N/A |
| 3/31/2021 | 37 | -6 | -6 | -5 | N/A |
| 12/31/2020 | 37 | -11 | -9 | -6 | N/A |
| 9/30/2020 | 39 | -10 | -8 | -5 | N/A |
| 6/30/2020 | 41 | -9 | -11 | -4 | N/A |
| 3/31/2020 | 41 | -12 | -11 | -5 | N/A |
| 12/31/2019 | 41 | -12 | -10 | -4 | N/A |
| 9/30/2019 | 40 | -11 | -10 | -3 | N/A |
| 6/30/2019 | 39 | -9 | N/A | -4 | N/A |
| 3/31/2019 | 37 | -7 | N/A | -5 | N/A |
| 12/31/2018 | 33 | -7 | N/A | -7 | N/A |
| 9/30/2018 | 29 | -8 | N/A | -5 | N/A |
| 6/30/2018 | 27 | -9 | N/A | -8 | N/A |
| 3/31/2018 | 25 | -8 | N/A | -6 | N/A |
| 12/31/2017 | 26 | -7 | N/A | -4 | N/A |
| 9/30/2017 | 26 | -10 | N/A | -6 | N/A |
| 6/30/2017 | 26 | -14 | N/A | -6 | N/A |
| 3/31/2017 | 26 | -14 | N/A | -6 | N/A |
| 12/31/2016 | 25 | -17 | N/A | -6 | N/A |
| 9/30/2016 | 25 | -15 | N/A | -9 | N/A |
| 6/30/2016 | 24 | -10 | N/A | -8 | N/A |
| 3/31/2016 | 24 | -9 | N/A | -6 | N/A |
| 12/31/2015 | 24 | -7 | N/A | -5 | N/A |
| 9/30/2015 | 24 | -6 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BNN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: BNN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BNN is expected to become profitable in the next 3 years.
Revenue vs Market: BNN's revenue (8.9% per year) is forecast to grow faster than the German market (6.2% per year).
High Growth Revenue: BNN's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BNN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/16 04:45 |
| End of Day Share Price | 2026/01/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BRAIN Biotech AG is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Meyer | Baader Helvea Equity Research |
| Jan Koch | Deutsche Bank |
| Yi-Dan Wang | Deutsche Bank |